ALSO NOTED: Quest Diagnostics buys HemoCue; Affymax pockets $10M milestone;Pozen to file response on Trexima; and much more...

> Quest Diagnostics has acquired Sweden's HemoCue, from the private equity firm EQT II for $420 million in cash. Release

> Affymax has nailed a $10 million milestone payment from Takeda. Release

> The FDA has called MGI Pharma's ad for a brain cancer drug "misleading." Report

> Pozen says it will file a response to the FDA on its Trexima migraine therapy in a few days. Report

> Aastrom has received an orphan drug designation for its Tissue Repair Cells used in chronic heart disease. Release

> Targacept is expanding its lab and office space in the Piedmont Triad Research Park. Release

> Generex is launching a Phase II trial for a breast cancer therapy. Release

> Heart muscle created from embryonic stem cells. Report

> New allergy vaccine works in a matter of weeks. Report

And Finally… A major new study concludes that fine grit in the air is a serious health threat to women, raising the risk of cardiovascular disease. Article